Abstract:Objective: This study explored the value of circulating tumor cells (CTC) detected by chromosome 8 centromere probe in diagnosis of non-small cell lung cancer (NSCLC) as well as correlation between CTC counts and clinical pathological characteristics. Methods: We collected 136 patients with newly diagnosed NSCLC (101 males and 35 females, age ranged from 34 to 79 years), 149 patients with non-malignant pulmonary diseases (103 males and 46 females, age ranged from 24 to 80 years) and 32 healthy volunteers (5 males and 27 females, age ranged from 24 to 42 years). Detection was performed using an epithelial cell adhesion molecule-independent strategy that combined immunocytochemistry staining (ICC) of CD(45) and fluorescence in situ hybridization detection (FISH) with chromosome 8 centromere probe (CEP8). CTC was defined as 4',6-diamidino-2-phenylindole (DAPI) positive, CD(45) negative and CEP8 more than 2 positive points. Quantitative data were reported as x±s and Mann Whitney test was used to compare them. Measurement data were analyzed as contingency tables and Pearson chi-squared test was used. P values of less than 0.05 were considered statistically significant. Results: CTCs were detected in 114 patients (83.8%) with NSCLC, 35 patients (23.5%) with non-malignant pulmonary diseases (P<0.000 1) and 5 volunteers (15.6%). CTC counts in NSCLC patients were (5.98±0.64) per 3.2 ml and (0.60±0.13) per 3.2 ml (P<0.000 1). A receiver operating characteristic curve (ROC) analysis showed similar capability of CTC count, with CEA, in discriminating NSCLC and non-malignant diseases with an area under ROC curve of 0.854 (95% confidence interval: 0.808-0.900, P<0.001). Cutoff of 2 circulating tumor cells per 3.2 ml peripheral blood gave the highest Youden Index of 0.614 in diagnosis of NSCLC with sensitivity of 72.1% (98/136) and specificity of 89.3% (133/149). When patients with CTC≥2/3.2 ml peripheral blood or serum CEA≥5 ng/ml were considered as having NSCLC, sensitivity and specificity of this combined test were 87.5% (119/136) and 85.9% (128/149), with a higher Youden Index of 0.734. No correlation was observed between positive rate of CTC (rate of patients with CTC≥2/3.2 ml peripheral blood) and age, gender, smoking status, pathologic types, and clinical stages. Conclusions: CTC counts detected by CD(45)-FISH is higher in NSCLC patients than in non-malignant disease patients. CTC≥2/3.2 ml peripheral blood is valuable in discriminating NSCLC from nonmalignant diseases, which can be more accurate when combined with CEA.

Clinical Evaluation Of Circulating Tumor Cells In Locally Advanced Nasopharyngeal Carcinoma: A Prospective Study.

The Frequency of Circulating Tumour Cells and the Correlation with the Clinical Response to Standard Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma: A Prospective Study.

Circulating Tumor Cells with Karyotyping As a Novel Biomarker for Diagnosis and Treatment of Nasopharyngeal Carcinoma

Detection and clinical significance of circulating tumor cells in peripheral blood of nasopharyngeal cancer patients with modified immunomagnetic enrichment and fluorescent immunocytochemistry

Detection of circulating tumor cells in peripheral blood of patients with nasopharyngeal carcinoma and evaluate its prognostic value

P2.03b-092 Predictive and Prognostic Effect of Circulating Tumor Cells in Non-Small Cell Lung Cancer Treated with Targeted Therapy: Topic: Biomarkers

[The Value of Circulating Tumor Cells Detected by Chromosome Centromere Probe Identification in Diagnosis of Non-Small Cell Lung Cancer].

Aneuploid Circulating Tumor Cells As a Predictor of Response to Neoadjuvant Chemotherapy in Non-Small Cell Lung Cancer

Circulating Tumor Cells and Evaluation of Targeted Therapy Effect in Egfr Mutation/Alk Translocation Metastatic Non-Small Cell Lung Cancer

P2.02-004 Real-time Monitoring of Circulating Tumor Cells to Evaluate Response of Neoadjuvant Chemotherapy in Locally Advanced NSCLC

Relationship of circulating tumor cells and Epstein-Barr virus DNA to progression-free survival and overall survival in metastatic nasopharyngeal carcinoma patients

Parametric Contrast-Enhanced Ultrasound As an Early Predictor of Radiation-Based Therapeutic Response for Lymph Node Metastases of Nasopharyngeal Carcinoma.

Clinical Significance Of Circulating Tumor Cells In Patients With Locally Advanced Head And Neck Squamous Cell Carcinoma

Epithelial-mesenchymal transition classification of circulating tumor cells predicts clinical outcomes in progressive nasopharyngeal carcinoma

Circulating Tumour Cells As Prognosis Predictive Markers of Neoadjuvant Chemotherapy-Treated Breast Cancer Patients.

Circulating Tumor Cells Correlate With Prognosis in Head and Neck Squamous Cell Carcinoma

Prognostic Importance of Circulating Tumor Cells in Non-Small Cell Lung Cancer: A Prospective Study

Combined Peripheral Natural Killer Cell and Circulating Tumor Cell Enumeration Enhance Prognostic Efficiency in Patients with Metastatic Triple-Negative Breast Cancer.

Combined Peripheral Natural Killer (NK) Cell and Circulating Tumor Cell (CTC) Enumeration to Enhance Prognostic Efficiency in Patients (pts) with Triple Negative Breast Cancer (TNBC)

Clinical utility of serial analysis of circulating tumour cells for detection of minimal residual disease of metastatic nasopharyngeal carcinoma

Pretreatment Platelet Count Improves the Prognostic Performance of the TNM Staging System and Aids in Planning Therapeutic Regimens for Nasopharyngeal Carcinoma: a Single-Institutional Study of 2,626 Patients.